XOMA Royalty (XOMA) Net Income Growth (3y) (2014 - 2026)

XOMA Royalty (XOMA) Net Income Growth (3y) (2014 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 9.16%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 38.43%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 13.80%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -3.84%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 79.26%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 XOMA Royalty 478.42 Mn 412.34 Mn - 33.95%

Historic Data

Download Data
DateValue
Mar 31, 2026 33.95%
Dec 31, 2025 51.24%
Jun 30, 2025 18.88%
Mar 31, 2025 46.11%
Dec 31, 2024 -32.38%
Sep 30, 2024 -57.23%
Jun 30, 2024 -129.55%
Mar 31, 2024 -13.51%
Dec 31, 2023 -42.57%
Sep 30, 2023 -125.13%
Jun 30, 2023 -70.10%
Mar 31, 2023 -32.50%
Dec 31, 2022 -13.16%
Sep 30, 2022 -87.69%
Jun 30, 2022 -72.26%
Mar 31, 2022 -38.46%
Dec 31, 2021 128.38%
Sep 30, 2021 1.04%
Jun 30, 2021 -4.74%
Mar 31, 2021 -24.66%